期刊
DRUG INFORMATION JOURNAL
卷 37, 期 2, 页码 155-158出版社
DRUG INFORMATION ASSOCIATION
DOI: 10.1177/009286150303700204
关键词
hepatotoxicity; safety data; review
In recent years, several postauthorization drugs were withdrawn or forced to issue major labeling warnings after major adverse events were reported to be associated with their use. As a result, considerable efforts have been made to improve the assessment of safety data generated from clinical trials to reduce these remedial events. Concerns about the drugs' hepatotoxicity are a major reason leading to these types of postauthorization actions. Measures to effectively predict warning signs of drugs that are hepatotoxic before they are authorized are being diligently pursued. The authors present their thoughts regarding the issues frequently encountered in the safety review of clinical hepatic data. Although these comments may not hold true for all types of data collected, and are not made on behalf of all regulatory agencies, it is hoped that these scientific discussions can help improve the safety review and, therefore, reduce postauthorization events that lead to irreversible liver damage.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据